Trajectory of response to esketamine nasal spray for treatment resistant depression: findings from ESCAPE-TRD.

A.H. Young, Lucie Bartova, N. Cardoner, Koen Demyttenaere, Andrea Fagiolini, Yordan Godinov, J.F. Golib Dzib, Christian von Holt, Roger S McIntyre, Albino J Oliveira-Maia, Benoit Rive, Philip Gorwood

Eur Psychiatry June 16, 2026 DOI: 10.1192/j.eurpsy.2026.12229 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Peer reviewed
Topics	Depression Esketamine

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Real-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: data from the enTRD registry European Psychiatry June 23, 2026
Analysis of trial confirms efficacy of esketamine nasal spray in TRD The Brown University Psychopharmacology Update March 1, 2025
Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray. International journal of psychiatry in clinical practice June 1, 2024 3 citations
Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology June 1, 2026 3 citations
Esketamine nasal spray for treatment-resistant depression: A retrospective multicenter real-world cohort study on effectiveness and suicidal outcomes. Journal of psychopharmacology (Oxford, England) March 21, 2026

Explore topics

Depression Esketamine

By condition and practice

Esketamine for depression Ketamine for depression

Study at a glance

Abstract

Related reading

Explore topics

By condition and practice